Semaglutide

Semaglutide is a long-acting single-target GLP-1 receptor agonist developed by Novo Nordisk, available in both injectable and oral tablet formulations as a widely used prescription peptide metabolic drug worldwide. It features high homology with human native GLP-1 and outstanding stability. With long-acting properties, excellent hypoglycemic and weight-loss effects, as well as cardiorenal protective benefits, it has become a benchmark drug in the fields of type 2 diabetes mellitus and chronic weight management

该产品以高纯度冻干粉末形式供应，确保了在各研究过程中的稳定性和可重复性。每批产品均遵循严格的质量标准生产，以支持可靠的实验室结果。

• 规格：40mg / 瓶
• 外观：白色冻干粉末
• 纯度：> 99% (HPLC验证)
• 储存条件：-20°C 以下避光保存
• 仅供实验室研究使用，非人类或临床用途。